The results showed that the acquired MRI T1 signal intensity was significantly increased in MDA-MB-231 cells treated with the Gd2O3@PCD-Glu NPs, indicating Gd2O3@PCD-Glu NPs could be applied as an MRI-targeted tumor agent to enhance GLUT1-overexpressed tumor theranostics. This evidence concerns the gene SLC2A1 and neoplasm.